Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2021

01-06-2021 | Metformin | Complications of HIV and Antiretroviral Therapy (GA McComsey, Section Editor)

Frailty and HIV: Moving from Characterization to Intervention

Authors: Kristine M. Erlandson, Damani A. Piggott

Published in: Current HIV/AIDS Reports | Issue 3/2021

Login to get access

Abstract

Purpose of Review

While the characteristics associated with frailty in people with HIV (PWH) have been well described, little is known regarding interventions to slow or reverse frailty. Here we review interventions to prevent or treat frailty in the general population and in people with HIV (PWH).

Recent Findings

Frailty interventions have primarily relied on nonpharmacologic interventions (e.g., exercise and nutrition). Although few have addressed frailty, many of these therapies have shown benefit on components of frailty including gait speed, strength, and low activity among PWH. When nonpharmacologic interventions are insufficient, pharmacologic interventions may be necessary. Many interventions have been tested in preclinical models, but few have been tested or shown benefit among older adults with or without HIV.

Summary

Ultimately, pharmacologic and nonpharmacologic interventions have the potential to improve vulnerability that underlies frailty in PWH, though clinical data is currently sparse.
Literature
1.
2.
•• Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. 2013;153(6):1194–217. https://​doi.​org/​10.​1016/​j.​cell.​2013.​05.​039This article delineates 9 primary pillars or hallmarks of aging processes across species that precipitate loss of physiological integrity, impaired function, and increased vulnerability to death. These pathways have been considered key targets for putative pharmacologic interventions to improve human health across the lifespan.CrossRefPubMedPubMedCentral
3.
Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci. 2007;62(11):1279–86.CrossRefPubMed
4.
5.
6.
7.
Xue QL, Bandeen-Roche K, Varadhan R, Zhou J, Fried LP. Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci. 2008;63(9):984–90.CrossRefPubMed
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
•• Erlandson KM, MaWhinney S, Wilson M, Gross L, McCandless SA, Campbell TB, et al. Physical function improvements with moderate or high-intensity exercise among older adults with or without HIV infection. AIDS. 2018;32(16):2317–26. https://​doi.​org/​10.​1097/​QAD.​0000000000001984​This interventional study compares two doses of exercises in people with and without HIV, providing some of the first data on the effect of exercise on frailty.CrossRefPubMed
23.
24.
Souza PM, Jacob-Filho W, Santarem JM, Zomignan AA, Burattini MN. Effect of progressive resistance exercise on strength evolution of elderly patients living with HIV compared to healthy controls. Clinics (Sao Paulo). 2011;66(2):261–6.CrossRef
25.
26.
27.
28.
• Montoya JL, Jankowski CM, O'Brien KK, Webel AR, Oursler KK, Henry BL, et al. Evidence-informed practical recommendations for increasing physical activity among persons living with HIV. AIDS. 2019;33(6):931–9. https://​doi.​org/​10.​1097/​QAD.​0000000000002137​Although little is known about the effects of exercise or physical activity on frailty in people with HIV, this comprehensive review presents the existing data on various components of health in people with HIV.CrossRefPubMed
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
Filteau S, PrayGod G, Woodd SL, Friis H, Heimburger DC, Koethe JR, et al. Nutritional status is the major factor affecting grip strength of African HIV patients before and during antiretroviral treatment. Tropical medicine & international health : TM & IH. 2017;22(10):1302–13. https://​doi.​org/​10.​1111/​tmi.​12929.CrossRef
41.
42.
43.
• Willig A, Wright L, Galvin TA. Practice paper of the Academy of Nutrition and Dietetics: nutrition intervention and human immunodeficiency virus infection. J Acad Nutr Diet. 2018;118(3):486–98. https://​doi.​org/​10.​1016/​j.​jand.​2017.​12.​007As nutrition is an important component of frailty, this article reviews current recommendation on nutrition recommendations for people with HIV.CrossRefPubMed
44.
• Lake JE, Stanley TL, Apovian CM, Bhasin S, Brown TT, Capeau J, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422–9. https://​doi.​org/​10.​1093/​cid/​cix178People aging with HIV may still experience lipohypertrophy and are now experiencing an increasing prevalence of obesity. This paper reviews what is currently known and provides practical management tips.CrossRefPubMedPubMedCentral
45.
46.
47.
48.
49.
50.
51.
Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci. 2004;59(3):255–63.CrossRefPubMed
52.
53.
54.
55.
56.
57.
58.
59.
Romera-Liebana L, Orfila F, Segura JM, Real J, Fabra ML, Möller M, et al. Effects of a primary care-based multifactorial intervention on physical and cognitive function in frail, elderly individuals: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2018;73(12):1688–74. https://​doi.​org/​10.​1093/​gerona/​glx259.CrossRefPubMed
60.
61.
62.
63.
64.
American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-94. https://​doi.​org/​10.​1111/​jgs.​15767.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Erlandson KM, Zhang L, Ng DK, Althoff KN, Palella F, Kingsley L, et al. Risk factors for falls, falls with injury, and falls with fracture among older men with or at risk of HIV infection. J Acquir Immune Def Syndr. 2019.
77.
Veeravelli S, Najafi B, Marin I, Blumenkron F, Smith S, Klotz SA. Exergaming in older people living with HIV improves balance, mobility and ameliorates some aspects of frailty. Journal of visualized experiments : JoVE. 2016;116. https://​doi.​org/​10.​3791/​54275.
78.
79.
Moore AA, Lake JE, Glasner S, Karlamangla A, Kuerbis A, Preciado D, et al. Establishing the feasibility, acceptability and preliminary efficacy of a multi-component behavioral intervention to reduce pain and substance use and improve physical performance in older persons living with HIV. J Subst Abus Treat. 2019;100:29–38. https://​doi.​org/​10.​1016/​j.​jsat.​2019.​02.​003.CrossRef
80.
81.
82.
Majnarić LT, Bekić S, Babič F, Pusztová Ľ, Paralič J. Cluster analysis of the associations among physical frailty, cognitive impairment and mental disorders. Medical science monitor : international medical journal of experimental and clinical research. 2020;26:e924281. https://​doi.​org/​10.​12659/​msm.​924281.CrossRef
83.
Erlandson KM, Perez J, Abdo M, Robertson K, Ellis RJ, Koletar SL, et al. Frailty, neurocognitive impairment, or both in predicting poor health outcomes among adults living with human immunodeficiency virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2019;68(1):131–8. https://​doi.​org/​10.​1093/​cid/​ciy430.CrossRef
84.
85.
86.
87.
88.
89.
90.
•• Siegler EL, Brennan-Ing M. Adapting systems of care for people aging with HIV. The Journal of the Association of Nurses in AIDS Care : JANAC. 2017;28(5):698–707. https://​doi.​org/​10.​1016/​j.​jana.​2017.​05.​006Involving a geriatrician in the care of people aging with HIV may help to maximize care and minimize progression to frailty. This review focuses on existing care models for older adults with HIV.CrossRefPubMed
91.
Levett T, Alford K, Roberts J, Adler Z, Wright J, Vera JH. Evaluation of a combined HIV and geriatrics clinic for older people living with HIV: The Silver Clinic in Brighton, UK. Geriatrics (Basel). 2020;5(4) 10.3390/geriatrics5040081.
92.
93.
94.
95.
96.
•• Gonzalez-Freire M, Diaz-Ruiz A, Hauser D, Martinez-Romero J, Ferrucci L, Bernier M, et al. The road ahead for health and lifespan interventions. Ageing Res Rev. 2020;59:101037. https://​doi.​org/​10.​1016/​j.​arr.​2020.​101037This article provides a survey of compounds selected for testing for antiaging activity in the National Institute of Aging’s Interventions Testing Program and a review of drugs in clinical trials targeting aging or age-related diseases in humans as identified in the ClinicalTrials.govdatabase.CrossRefPubMedPubMedCentral
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
• Rabassa M, Zamora-Ros R, Urpi-Sarda M, Bandinelli S, Ferrucci L, Andres-Lacueva C, et al. Association of habitual dietary resveratrol exposure with the development of frailty in older age: the Invecchiare in Chianti study. Am J Clin Nutr. 2015;102(6):1534–42. https://​doi.​org/​10.​3945/​ajcn.​115.​118976This was a longitudinal study of persons aged 65 years and older from the Aging in Chianti study. The combination of total dietary resveratrol and total urinary resveratrol was found to be inversely associated with frailty risk over 3 years of follow-up.CrossRefPubMedPubMedCentral
136.
137.
Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62(4):1186–95. https://​doi.​org/​10.​2337/​db12-0975.CrossRefPubMedPubMedCentral
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
• Wang CP, Lorenzo C, Espinoza SE. Frailty attenuates the impact of metformin on reducing mortality in older adults with type 2 diabetes. Journal of endocrinology, diabetes & obesity. 2014;2(2) In this cross-sectional observational study of 2415 veterans, metformin use was associated with a significantly decreased odds of frailty compared to sulfonylurea usage.
168.
Laksmi PW, Setiati S, Tamin TZ, Soewondo P, Rochmah W, Nafrialdi N, et al. Effect of metformin on handgrip strength, gait speed, myostatin serum level, and health-related quality of life: a double blind randomized controlled trial among non-diabetic pre-frail elderly patients. Acta Med Indones. 2017;49(2):118–27.PubMed
169.
170.
• Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060–5. https://​doi.​org/​10.​1016/​j.​cmet.​2016.​05.​011This article provides an overview of the data informing the use of metformin in the Targeting Aging with Metformin (TAME) trial – a trial with a planned enrollment of 3000 older adults aged 65-79 years to examine the effect of metformin on the development of aging-related conditions, including frailty.CrossRefPubMedPubMedCentral
171.
172.
173.
174.
175.
176.
177.
178.
179.
180.
181.
182.
183.
184.
185.
186.
187.
188.
189.
190.
191.
192.
193.
194.
195.
•• Pazan F, Petrovic M, Cherubini A, Onder G, Cruz-Jentoft AJ, Denkinger M, et al. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials. Eur J Clin Pharmacol. 2020. https://​doi.​org/​10.​1007/​s00228-020-02951-8This article is a systematic review of randomized controlled trials examining pharmacologic interventions targeting frailty parameters among adults 60 years and older.
196.
Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al. Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci. 2011;66(10):1090–9. https://​doi.​org/​10.​1093/​gerona/​glr100.CrossRefPubMed
197.
198.
199.
200.
Liu PY, Wishart SM, Handelsman DJ. A double-blind, placebo-controlled, randomized clinical trial of recombinant human chorionic gonadotropin on muscle strength and physical function and activity in older men with partial age-related androgen deficiency. J Clin Endocrinol Metab. 2002;87(7):3125–35. https://​doi.​org/​10.​1210/​jcem.​87.​7.​8630.CrossRefPubMed
201.
• Erlandson KM, Ng DK, Jacobson LP, Margolick JB, Dobs AS, Palella FJ Jr, et al. Inflammation, immune activation, immunosenescence, and hormonal biomarkers in the frailty-related phenotype of men with or at risk for HIV infection. J Infect Dis. 2017;215(2):228–37. https://​doi.​org/​10.​1093/​infdis/​jiw523This study demonstrated the significant association of low free testosterone levels with frailty in HIV.CrossRefPubMed
202.
203.
204.
205.
206.
• Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. Jama. 2000;283(6):763–70. https://​doi.​org/​10.​1001/​jama.​283.​6.​763In this randomized controlled trial of men with HIV with low testosterone levels aged 18–50 years, 16 weeks of testosterone administration with or without resistance exercise increased muscle strength and lean body mass.CrossRefPubMedPubMedCentral
207.
208.
209.
210.
Beyer I, Bautmans I, Njemini R, Demanet C, Bergmann P, Mets T. Effects on muscle performance of NSAID treatment with piroxicam versus placebo in geriatric patients with acute infection-induced inflammation. A double blind randomized controlled trial BMC Musculoskelet Disord. 2011;12:292. https://​doi.​org/​10.​1186/​1471-2474-12-292.CrossRefPubMed
211.
212.
•• Piggott DA, Erlandson KM, Yarasheski KE. Frailty in HIV: epidemiology, biology, measurement, interventions, and research needs. Current HIV/AIDS reports. 2016. 10.1007/s11904-016-0334-8. This article reviews the epidemiology of and provides an integrative research framework for frailty in HIV.
213.
•• Piggott DA, Bandeen-Roche K, Mehta SH, Brown TT, Yang H, Walston JD, et al. Frailty transitions, inflammation, and mortality among persons aging with HIV infection and injection drug use. Aids. 2020;34(8):1217–25. https://​doi.​org/​10.​1097/​QAD.​0000000000002527​This longitudinal study of frailty transitions among HIV-infected and uninfected persons demonstrated the significant association of higher socioeconomic status, lower comorbidity, ART-mediated HIV virologic suppression, and lower levels of inflammation with reduced frailty progression and greater frailty recovery.CrossRefPubMed
214.
215.
•• Fukui SM, Piggott DA, Erlandson KM. Inflammation strikes again: frailty and HIV. Current HIV/AIDS reports. 2018;15(1):20–9. https://​doi.​org/​10.​1007/​s11904-018-0372-5This article reviews evidence for the relationship between inflammation and frailty in HIV and putative targets for inflammation-based interventions for frailty in HIV.CrossRefPubMed
216.
217.
National Academies of Sciences, Engineering, and Medicine 2017. Communities in action: pathways to health equity. Washington, DC: The National Academies Press. Available at: 10.17226/24624. Accessed April 14, 2020.
218.
219.
220.
221.
222.
Lesko CR, Cole SR, Miller WC, Westreich D, Eron JJ, Adimora AA, et al. Ten-year survival by race/ethnicity and sex among treated, HIV-infected adults in the United States. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015;60(11):1700–7. https://​doi.​org/​10.​1093/​cid/​civ183.CrossRef
223.
224.
Losina E, Schackman BR, Sadownik SN, Gebo KA, Walensky RP, Chiosi JJ, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009;49(10):1570–8. https://​doi.​org/​10.​1086/​644772.CrossRef
225.
226.
227.
Siddiqi AE, Hu X, Hall HI. Centers for Disease C, Prevention. Mortality among blacks or African Americans with HIV infection—United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2015;64(4):81–6.PubMedPubMedCentral
228.
229.
230.
231.
232.
233.
234.
•• Bandeen-Roche K, Seplaki CL, Huang J, Buta B, Kalyani RR, Varadhan R, et al. Frailty in older adults: a nationally representative profile in the United States. J Gerontol A Biol Sci Med Sci. 2015;70(11):1427–34. https://​doi.​org/​10.​1093/​gerona/​glv133This nationally representative study of adults 65 years and older in the United States found frailty prevalence to be significantly higher among racial and ethnic minorities and persons of lower income.CrossRefPubMedPubMedCentral
235.
•• Dugravot A, Fayosse A, Dumurgier J, Bouillon K, Rayana TB, Schnitzler A, et al. Social inequalities in multimorbidity, frailty, disability, and transitions to mortality: a 24-year follow-up of the Whitehall II cohort study. Lancet Public Health. 2020;5(1):e42–50. https://​doi.​org/​10.​1016/​S2468-2667(19)30226-9In this longitudinal UK-based study of adults enrolled between the ages of 35 and 55 years and followed for a median of ~24 years, lower socioeconomic status was significantly associated with a greater likelihood of transition to a frail state.CrossRefPubMed
236.
237.
238.
239.
Metadata
Title
Frailty and HIV: Moving from Characterization to Intervention
Authors
Kristine M. Erlandson
Damani A. Piggott
Publication date
01-06-2021
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2021
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-021-00554-1

Other articles of this Issue 3/2021

Current HIV/AIDS Reports 3/2021 Go to the issue

eHealth and HIV (J Simoni and J Stekler, Section Editors)

Ethical Implications of eHealth Tools for Delivering STI/HIV Laboratory Results and Partner Notifications

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Neuroimaging the Neuropathogenesis of HIV

Implementation Science (E Geng, Section Editor)

Implementing Implementation Research: Teaching Implementation Research to HIV Researchers

eHealth and HIV (J Simoni and J Stekler, Section Editors)

Use of eHealth for HIV Medical Education: a Narrative Review

eHealth and HIV (J Simoni and J Stekler, Section Editors)

Machine Learning and Clinical Informatics for Improving HIV Care Continuum Outcomes

HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)

Probing the Interface of HIV and Inflammaging
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits